CHMP nods for Arzerra, Halaven and Vfend extensions
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approving the extension of the indications for three approved medicines, Arzerra, Halaven and Vfend.